CD276, also known as (B7-H3) , is a type I transmembrane protein. The extracellular region contains two pairs of the same immunoglobulin variable and constant regions. The intracellular region is very short and has no clear signal motif. The expression of its mRNA level is relatively extensive, but the protein expression is relatively limited to non-immune cells such as resting fibroblasts, endothelial cells, osteoblasts, amniotic fluid stem cells, as well as induced antigen-presenting cells and the surface of NK cells ^{[1, 3]} . Many studies have revealed that B7-H3 is overexpressed in a variety of tumors, including melanoma, leukemia, breast cancer, prostate cancer, colorectal cancer and other tumors, and its expression level is closely related to the poor prognosis and clinical outcome of patients ^{[2 ]} It is speculated that it is involved in tumor immune evasion. Although its molecular mechanism is still unclear, as a possible immune checkpoint molecule, it is a promising target for tumor immunotherapy.

This product is a mouse monoclonal antibody targeting CD276 , which can be used for flow cytometric detection of over-expressing CD276 cell lines or activity detection of CD276 recombinant protein.

Product name: CD276 monoclonal antibody

Reactivity: human

Subclass: mouse IgG

Concentration: 1μg/μL

Analysis instrument: flow cytometer

Purification method: affinity chromatography

Storage system: PBS, pH 7.4, 20% glycerol

Storage conditions: -20°C refrigerator, avoid repeated freezing and thawing

Illustration：Lane M on the left is the protein MW marker, Lane 1 is the 10ug CD276 mouse monoclonal antibody;

The picture on the right shows the FACS of CD276 expression

Reference materials:

1. B7-H3: A Costimulatory Molecule for T Cell Activation and IFN-gamma Production

2. Molecular Pathways: Targeting B7-H3 (CD276) for Human Cancer Immunotherapy

3. B7-H3 Promotes Acute and Chronic Allograft Rejection